Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Laser therapy may reduce the severity of symptoms and speed healing of oral mucositis. It is not yet known if laser therapy is effective in preventing oral mucositis.

PURPOSE: Randomized phase II/III trial to determine the effectiveness of laser therapy in preventing oral mucositis in patients who are undergoing bone marrow transplantation.


Clinical Trial Description

OBJECTIVES: I. Determine whether low-energy laser therapy can prevent oral mucositis in patients undergoing bone marrow transplantation.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to one of three treatment arms. Arm I: Patients undergo low-energy laser therapy with visible red light (650 nm) daily over 15-20 minutes beginning on the first day of their transplant conditioning regimen and continuing until day 2 after bone marrow transplantation. Arm II: Patients undergo low-energy laser therapy with invisible infra-red light (780 nm) daily on the same schedule as in arm I. Arm III: Patients undergo sham laser therapy daily on the same schedule as in arm I. Patients are followed on days 3, 7, 10, 14, 18, 21, and 24.

PROJECTED ACCRUAL: A total of 66 patients (22 per treatment arm) will be accrued for this study. ;


Study Design

Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT00024037
Study type Interventional
Source Fred Hutchinson Cancer Research Center
Contact
Status Completed
Phase Phase 2/Phase 3
Start date April 1995
Completion date December 2002

See also
  Status Clinical Trial Phase
Completed NCT00003313 - Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer Phase 3
Completed NCT02015559 - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus Phase 2
Completed NCT00008398 - Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase 3
Completed NCT00004256 - Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer Phase 2
Terminated NCT02273752 - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Phase 2
Terminated NCT00003686 - Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids Phase 3
Completed NCT00036881 - Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer Phase 3
Completed NCT00004061 - Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer Phase 2
Completed NCT00003139 - Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase 3
Completed NCT00017511 - Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Phase 3
Completed NCT00003580 - Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer Phase 2
Completed NCT05039593 - Oral Care Frequency in Mechanically Ventilated Patients N/A
Terminated NCT00025298 - Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx Phase 2
Recruiting NCT00036712 - Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Phase 2
Completed NCT00004132 - Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer Phase 2
Completed NCT00003898 - Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation Phase 2
Completed NCT00003193 - Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer Phase 1/Phase 2
Completed NCT00002533 - Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Phase 2/Phase 3
Active, not recruiting NCT01085617 - Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase 3
Completed NCT00004234 - Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Phase 3